Abstract:Pharmaceutical companies continuously face challenges to deliver new drugs with true medical value. R&D productivity of drug development projects depends on 1) the value of the drug concept and 2) data and in-depth knowledge that are used rationally to evaluate the drug concept's validity. A model-based data-intensive drug development approach is a key competitive factor used by innovative pharmaceutical companies to reduce information bias and rationally demonstrate the value of drug concepts. Owing to the accumulation of publicly available biomedical information, our understanding of the pathophysiological mechanisms of diseases has developed considerably; it is the basis for identifying the right drug target and creating a drug concept with true medical value. Our understanding of the pathophysiological mechanisms of disease animal models can also be improved; it can thus support rational extrapolation of animal experiment results to clinical settings. The Systems Biology approach, which leverages publicly available transcriptome data, is useful for these purposes. Furthermore, applying Systems Pharmacology enables dynamic simulation of drug responses, from which key research questions to be addressed in the subsequent studies can be adequately informed. Application of Systems Biology/Pharmacology to toxicology research, namely Systems Toxicology, should considerably improve the predictability of drug-induced toxicities in clinical situations that are difficult to predict from conventional preclinical toxicology studies. Systems Biology/Pharmacology/Toxicology models can be continuously improved using iterative learn-confirm processes throughout preclinical and clinical drug discovery and development processes. Successful implementation of data-intensive drug development approaches requires cultivation of an adequate R&D culture to appreciate this approach.

[Advancing the drug discovery ecosystem for innovative medicines]

Strengthening the Competitiveness of Japan's Pharmaceutical Industry: Analysis of Country Differences in the Origin of New Drugs and Japan's Highly Productive Firm.

Two decades of new drug approvals in Japan

Increased contribution of small companies to late-entry drugs: a changing trend in FDA-approved drugs during the 2020s

Adaptive Enterprise Architecture for the Digital Healthcare Industry: A Digital Platform for Drug Development

A case study of visualization to assess the progress of drug discovery research projects in academia: the possibility of building a support system based on common milestones for facilitating collaboration with industry

Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates

Current status of drug development in Tohoku University Hospital (CRIETO).

i Drug: a web-accessible and interactive drug discovery and design platform

Data-intensive drug development in the information age: applications of Systems Biology/Pharmacology/Toxicology

An Empirical Analysis of Japan's Drug Development Lag Behind the United States

Keep Up the Pace of Drug Development Evolution and Expenditure

The New Era of Drug Discovery: The Power of Computer-aided Drug Design (CADD)

Different Development Strategies Affecting Japan's Drug lag between Japan-Based and Foreign-Based Companies

Strategic partnerships for AI-driven drug discovery: The role of relational dynamics

Academic drug discovery: Challenges and opportunities

Accelerating Pharmaceutical Research and Development through AI-Driven Drug Discovery

Drug discovery in the next decade: innovation needed ASAP

[Current Status and Regulatory Issues of Companion Diagnostics in Japan]

[Omics and cell controlling technology for drug discovery]

Employing Artificial Intelligence Methods in Drug Development: A New Era in Medicine